David Chung

Northwell Health Cancer Institute | System Chief, Multiple Myeloma | Director, Clinical Research

[CIBMTR @CIBMTR]

A personalized vaccine helps produce cells that fight multiple myeloma. But it’s unclear if the vaccine stops multiple myeloma from worsening. Read more about this @BMTCTN study: https://t.co/OrLiZ2db2Y

[David Chung @DavidJChungMD]

For #BMT apply@
https://t.co/uq4Wjx4Ft7

[David Chung @DavidJChungMD]

For #cancer_immunotherapy apply@
https://t.co/5QOiswxoSd

[David Chung @DavidJChungMD]

Interested in an academic career in #BMT or #cancer_immunotherapy? Apply for an advanced fellowship @sloan_kettering. Develop clinical expertise while engaging in novel clinical and translational research. March 1 deadline fast approaching.

[Gunjan Shah @GunjanLShah]

Congratulation @MScordoMD ! Fludarabine exposure and CAR T cell outcomes in the largest room possible!

[David Chung @DavidJChungMD]

#ASH22 today 3PM Noriko Nishimura will present our data that stem cell autograft MRD negativity improves MM autotransplant outcomes. @MSKCancerCenter #mmsm #bmtsm https://t.co/JF1XY8V7y9

[Nina Shah @ninashah33]

One of my fave collaborators of all time-David Avigan with a beautiful discussion of how we might take advantage of the immune system to improve our immunotherapies in #myeloma #mmsm #IMS2022

[David Chung @DavidJChungMD]

Featured today by @MSKLibrary: Langerhans dendritic cell vaccine bearing mRNA-encoded tumor antigens induces antimyeloma immunit... https://t.co/hDdtd1LVOs

[Blood Cancer Discovery @BCD_AACR]

Referenced in the #AACRCOVIDReport: Disease and therapy-specific impact on humoral immune responses to #COVID19 vaccination in hematologic malignancies by Chung, Knorr, et al. https://t.co/31xcuuIaDM

[David Chung @DavidJChungMD]

New First Edition article: Langerhans dendritic cell vaccines bearing mRNA-encoded tumor antigens induce anti-myeloma immunity after autotransplant. https://t.co/FkRlxogq1b @BloodAdvances #mmsm #CancerVaccine

[David Chung @DavidJChungMD]

For #cancer_immunotherapy apply@ https://t.co/5QOiswwR2F

[David Chung @DavidJChungMD]

For #BMT apply@ https://t.co/uq4Wjx47Dz

[David Chung @DavidJChungMD]

Reminder: Interested in an academic career in #BMT or #cancer_immunotherapy? Apply for an advanced fellowship @sloan_kettering. Develop clinical expertise while engaging in exciting and novel clinical and translational research. March 1 deadline.

[David Chung @DavidJChungMD]

@ninashah33 Haha, yes there are! Now you know. Follow me to make life easier in the future

[Daniel Auclair @AuclairDan]

More on this study #ASH21 #mmsm

[David Chung @DavidJChungMD]

#ASH21 Today 7:15PM Impact of Autologous Hematopoietic Cell Transplant Followed By Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance in Increasing Multiple Myeloma Immunity (BMT CTN 1401) @BMTCTN @ninashah33 @mpasca David Avigan https://t.co/ssx2XoZgC1

[Blood Cancer Discovery @BCD_AACR]

For today's #ASH21 Q&A on #covid vaccines in immunocompromised patients, check out two @BCD_AACR articles in the current issue, and a commentary from Antoni Ribas, et al, on vaccines in #bloodcancer patients. https://t.co/vq0k1FAB0N

[David Chung @DavidJChungMD]

@RSambhava @sloan_kettering Sorry but we require formal H/O training ☹️

[David Chung @DavidJChungMD]

Interested in an academic career in #BMT or #cancer_immunotherapy? Apply for an advanced fellowship @sloan_kettering. Develop clinical expertise while engaging in exciting and novel clinical and translational research. March 1 deadline.

[David Chung @DavidJChungMD]

@RSambhava @sloan_kettering Yes, completion of heme onc fellowship or equivalent required